Skip to main content
. 2017 Feb 6;8(10):16642–16649. doi: 10.18632/oncotarget.15120

Table 4. CF-DNA quantity (ng) in relation to patient prognosis.

Gene Overall(n = 79) Non-relapsed(n = 58) Relapsed(n = 21) p-value#
Median (iqr range) Median (iqr range) Median (iqr range)
HER2 LONG 0.034 (0.011–0.137) 0.032 (0.014–0.121) 0.049 (0.007–0.137) 0.868
HER2 SHORT 0.238 (0.093–0.509) 0.206 (0.087–0.466) 0.409 (0.123–0.890) 0.078
BCAS1 LONG 0.266 (0.131–0.941) 0.238 (0.093–0.798) 0.292 (0.169–0.970) 0.339
BCAS1 SHORT 1.269 (0.536–2.133) 1.277 (0.525–2.275) 1.269 (0.677–2.069) 0.824
MYC LONG 0.421 (0.146–1.205) 0.364 (0.164–1.379) 0.485 (0.120–1.048) 0.965
MYC SHORT 1.145 (0.557–2.255) 1.136 (0.557–2.246) 1.185 (0.689–2.255) 0.689
PI3KCA LONG 0.108 (0.036–0.373) 0.082 (0.032–0.315) 0.195 (0.049–0.472) 0.226
PI3KCA SHORT 1.619 (0.296–4.332) 1.630 (0.251–3.198) 1.619 (0.338–4.365) 0.549

#Two-sample Wilcoxon rank-sum (Mann-Whitney) test.